hotspot -WSS

hotspot

author：knowledge 2025-10-01 18:33:55 - browse：6946

Two people stare at a keyhole in a human head in between them, as the short-haired person on the left holds a key — first opinion coverage from STAT — Adobe

In many ways, psychiatry is still flying blind. People experiencing mental health conditions are prescribed various drugs until one (or a combination) finally works — a painful process that can take years. As a psychiatrist and neuroscientist, I became increasingly impatient and frustrated with this ineffective way of treating patients. This guided the core question behind my research: Can biology explain how people with the same psychiatric disorder respond differently to the same treatment?

Since I first began exploring this question more than a decade ago, mental illness has become a global epidemic. Despite significant efforts, progress in psychiatric drug development has remained disappointingly slow. There have been a few notable approvals in recent years, and a renewal of interest by Big Pharma, following a retreat from psychiatric research in the mid to late 2000s. But the landscape remains predominantly marked by failures and a dry drug development pipeline. Approved drugs follow the same pattern of prescribing via guesswork, with most patients not responding to a given drug. This cycle of trial-and-error drug development producing trial-and-error treatment arises from a simple source: We have not systematized a process for learning from our failures and successes.

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

For example, take depression: While the rise of selective serotonin reuptake inhibitors (SSRIs) in the 1980s and 1990s seemed to provide a solution, seminal studies in the 2000s exposed fundamental limitations of our treatment options. Antidepressants are widely prescribed, but their efficacy relative to placebo is modest.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Stem cell clinics for heart failure: buyer be wary

Wikipedia

focus

WSS

Roivant's CEO is a star, but biotech's black hole persists

J&J lung cancer data amount to new salvo against AstraZeneca

Microsoft strikes partnership with Duke Health to advance health AI

Influencer to be charged after chaos erupts in New York City's Union Square

Readout LOUD podcast: Live from the 2023 STAT Summit

What Mike Pence has said that could be used in a Donald Trump trial

hotspot

hotspot

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

knowledge

Medicare proposal to cover medical devices draws a mixed reaction

How AI can help patients find reliable information about doctors

Supreme Court strikes down use of affirmative action

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

OTC birth control: A brief history of over the counter pill design

In age of alternative facts, a scholarly course on calling out crap

For BCIs, commercial hurdles may be bigger than scientific ones

Hepatitis C has a cure — but many Americans still lack access to it

Study on Amgen’s bispecific immunotherapy produces positive data

leisure time

Cassava Sciences’ Alzheimer’s clinical trials should be halted

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

FDA clears Verve to begin U.S. study of gene

FDA clears Verve to begin U.S. study of gene

Merck, Daiichi strike cancer drug pact worth up to $22 billion

STAT Summit: The economic case for universal basic health care

Wikipedia

focus

focus

knowledge